Literature DB >> 26051280

The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis.

Yi-Yong Baek1, Dong-Keon Lee1, Ju-Hoon So2, Cheol-Hee Kim2, Dooil Jeoung3, Hansoo Lee4, Jongseon Choe5, Moo-Ho Won6, Kwon-Soo Ha1, Young-Guen Kwon7, Young-Myeong Kim8.   

Abstract

Kringle 5, derived from plasminogen, is highly capable of inhibiting angiogenesis. Here, we have designed and synthesized 10 tetrapeptides, based on the amino acid properties of the core tetrapeptide Lys-Leu-Tyr-Asp (KLYD) originating from anti-angiogenic kringle 5 of human plasminogen. Of these, Arg-Leu-Tyr-Glu (RLYE) effectively inhibited vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, migration and tube formation, with an IC50 of 0.06-0.08 nM, which was about ten-fold lower than that of the control peptide KLYD (0.79 nM), as well as suppressed developmental angiogenesis in a zebrafish model. Furthermore, this peptide effectively inhibited the cellular events that precede angiogenesis, such as ERK and eNOS phosphorylation and nitric oxide production, in endothelial cells stimulated with VEGF. Collectively, these data demonstrate that RLYE is a potent anti-angiogenic peptide that targets the VEGF signaling pathway.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; ERK; Endothelial cells; Tetrapeptide; eNOS

Mesh:

Substances:

Year:  2015        PMID: 26051280     DOI: 10.1016/j.bbrc.2015.05.073

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.

Authors:  Yi-Yong Baek; Dong-Keon Lee; Joohwan Kim; Ji-Hee Kim; Wonjin Park; Taesam Kim; Sanghwa Han; Dooil Jeoung; Ji Chang You; Hansoo Lee; Moo-Ho Won; Kwon-Soo Ha; Young-Guen Kwon; Young-Myeong Kim
Journal:  Oncotarget       Date:  2017-02-14

2.  Arg-Leu-Tyr-Glu Suppresses Retinal Endothelial Permeability and Choroidal Neovascularization by Inhibiting the VEGF Receptor 2 Signaling Pathway.

Authors:  Wonjin Park; Yi-Yong Baek; Joohwan Kim; Dong Hyun Jo; Seunghwan Choi; Jin Hyoung Kim; Taesam Kim; Suji Kim; Minsik Park; Ji Yoon Kim; Moo-Ho Won; Kwon-Soo Ha; Jeong Hun Kim; Young-Guen Kwon; Young-Myeong Kim
Journal:  Biomol Ther (Seoul)       Date:  2019-05-02       Impact factor: 4.634

3.  Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.

Authors:  Hye Cheong Koo; Yi-Yong Baek; Jun-Sup Choi; Young-Myeong Kim; Bokyung Sung; Min-Jung Kim; Jae Gyu Kim; Ji Chang You
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.